JP2025511875A5 - - Google Patents
Info
- Publication number
- JP2025511875A5 JP2025511875A5 JP2024559442A JP2024559442A JP2025511875A5 JP 2025511875 A5 JP2025511875 A5 JP 2025511875A5 JP 2024559442 A JP2024559442 A JP 2024559442A JP 2024559442 A JP2024559442 A JP 2024559442A JP 2025511875 A5 JP2025511875 A5 JP 2025511875A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkoxy
- cycloalkyl
- disease
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263327058P | 2022-04-04 | 2022-04-04 | |
| US63/327,058 | 2022-04-04 | ||
| PCT/US2023/063745 WO2023196720A2 (en) | 2022-04-04 | 2023-03-04 | Lrrk2 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025511875A JP2025511875A (ja) | 2025-04-16 |
| JP2025511875A5 true JP2025511875A5 (enExample) | 2026-01-08 |
Family
ID=88243544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024559442A Pending JP2025511875A (ja) | 2022-04-04 | 2023-03-04 | Ｌｒｒｋ２阻害剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250248998A1 (enExample) |
| EP (1) | EP4504722A4 (enExample) |
| JP (1) | JP2025511875A (enExample) |
| KR (1) | KR20240171138A (enExample) |
| CN (1) | CN119183452A (enExample) |
| AU (1) | AU2023249498B2 (enExample) |
| CA (1) | CA3247536A1 (enExample) |
| CL (1) | CL2024003023A1 (enExample) |
| MX (1) | MX2024012306A (enExample) |
| TW (1) | TWI867484B (enExample) |
| WO (1) | WO2023196720A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023007793A (es) | 2020-12-30 | 2023-09-22 | Tyra Biosciences Inc | Compuestos de indazol como inhibidores de cinasas. |
| WO2024209363A1 (en) | 2023-04-06 | 2024-10-10 | Pfizer Inc. | Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators |
| WO2025123046A1 (en) * | 2023-12-07 | 2025-06-12 | Arvinas Operations, Inc. | Synthesis of leucine-rich repeat kinase 2 modulators |
| CN121045151A (zh) * | 2024-05-31 | 2025-12-02 | 中国医学科学院药物研究所 | 一类氧代芳杂环结构的cd73抑制剂、及其制法和药物组合物与用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2489663A1 (en) * | 2011-02-16 | 2012-08-22 | Almirall, S.A. | Compounds as syk kinase inhibitors |
| WO2014134774A1 (en) * | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| EP3694330B1 (en) * | 2017-10-11 | 2023-04-19 | Merck Sharp & Dohme LLC | Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof |
| US20210361774A1 (en) * | 2018-10-16 | 2021-11-25 | Dana-Farber Cancer Institute, Inc. | Degraders of wild-type and mutant forms of lrrk2 |
| CA3211347A1 (en) * | 2021-03-19 | 2022-09-22 | Erika Araujo | Indazole based compounds and associated methods of use |
| TW202317561A (zh) * | 2021-07-01 | 2023-05-01 | 美商羅曼德生物治療公司 | 作為治療劑的具有１ｈ—吡唑并［４，３—ｃ］吡啶—６—胺基的化合物 |
-
2023
- 2023-03-04 EP EP23785521.8A patent/EP4504722A4/en active Pending
- 2023-03-04 WO PCT/US2023/063745 patent/WO2023196720A2/en not_active Ceased
- 2023-03-04 CN CN202380040105.7A patent/CN119183452A/zh active Pending
- 2023-03-04 AU AU2023249498A patent/AU2023249498B2/en active Active
- 2023-03-04 CA CA3247536A patent/CA3247536A1/en active Pending
- 2023-03-04 JP JP2024559442A patent/JP2025511875A/ja active Pending
- 2023-03-04 US US18/854,031 patent/US20250248998A1/en active Pending
- 2023-03-04 KR KR1020247036645A patent/KR20240171138A/ko active Pending
- 2023-03-30 TW TW112112228A patent/TWI867484B/zh active
-
2024
- 2024-10-03 MX MX2024012306A patent/MX2024012306A/es unknown
- 2024-10-04 CL CL2024003023A patent/CL2024003023A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2928147T3 (es) | Compuesto de 1H-imidazo[4,5-H]quinazolina como inhibidor de proteincinasas | |
| JP5567599B2 (ja) | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤 | |
| US10947205B2 (en) | Oxazolidinone compounds and methods of use thereof as antibacterial agents | |
| JP7515467B2 (ja) | Ｖａｐ－１の阻害剤 | |
| JP2017025080A (ja) | カゼインキナーゼ１δ（ＣＫ１δ）阻害剤及びタウオパチーなどの神経変性疾患の治療におけるその使用 | |
| AU2017254523A1 (en) | Compounds and compositions for treating conditions associated with NLRP activity | |
| JP2008520589A5 (enExample) | ||
| US20190314347A1 (en) | Substituted pyridinone-containing trycyclic compounds, and methods using same | |
| KR20210121044A (ko) | 치환된 폴리사이클릭 카복실산, 이의 유사체, 및 이의 사용 방법 | |
| KR20220130697A (ko) | 새로운 화합물 및 그 용도 | |
| RU2297420C2 (ru) | Средство против кислотоустойчивых бактерий, содержащее гетероциклические производные бензоксазина в качестве активного компонента | |
| US8980922B2 (en) | 5-HT4 receptor agonists for the treatment of dementia | |
| JP2005514370A5 (enExample) | ||
| RU2006113942A (ru) | Производные бензимидазолона и хиназолина как ангонисты orl-рецепторов человека | |
| JP2009526834A5 (enExample) | ||
| JP2007516292A5 (enExample) | ||
| PT99901B (pt) | Processo para preparacao de novos derivados da 3,4-dihidro-isoquinolina e de composicoes farmaceuticas que os contem | |
| CA3154481A1 (en) | Methods of detecting neurological disorders via binding to phosphorylated tau protein | |
| JP4728640B2 (ja) | ニューロトロフィン関連疾患の治療用医薬組成物 | |
| BR112019015834A2 (pt) | Compostos, composição farmacêutica, kit e uso de um composto ou uma composição | |
| JP4216337B2 (ja) | ベンゾ［ｇ］キノリン誘導体 | |
| CN104981238A (zh) | 抗细菌化合物 | |
| WO2011046901A2 (en) | Broad spectrum antiviral and methods of use | |
| RU2794494C2 (ru) | Оксазолидиноновые соединения и способы их применения в качестве противобактериальных средств | |
| TW202537626A (zh) | 含磷ｂｃｌ抑制劑及抗衰老化合物及其用途 |